Elranatamab for newly diagnosed plasmablastic lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy, Infections clinical trials.
This trial tests a new drug called elranatamab in patients with plasmablastic lymphoma (a rare blood cancer) who have already completed their first treatment. The drug may help prevent the cancer from coming back or growing, and the trial includes patients with and without HIV.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have plasmablastic lymphoma that was confirmed by biopsy and you've completed your first cancer treatment with good response (partial or complete remission)
- Your blood counts have recovered to safe levels (absolute neutrophil count ≥500 cells/mcL, platelets ≥50,000 cells/mcL)
- You have had stable disease or better after your first treatment (not progressive disease)
- You have a tumor tissue sample available for testing to check if your cancer expresses BCMA (a protein the drug targets)
- If you have HIV, you must be on effective HIV medications with a CD4 count ≥50 cells/mcL
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests how well a combination of daratumumab, bortezomib, and dexamethasone works in people with plasmablastic lymphoma that has returned or did not respond to prior treatment. It aims to shrink measurable tumors and improve outcomes, including for some people living with HIV.
This early-phase trial tests daratumumab combined with a dose-adjusted chemotherapy plan (EPOCH) to treat plasmablastic lymphoma. It aims to improve how well the cancer responds, including in people living with HIV or without HIV.
This study tests whether a new antibody drug called elranatamab can help treat newly diagnosed AL amyloidosis (a disease where abnormal proteins build up in organs). If you haven't had treatment yet and have confirmed AL amyloidosis, this trial may offer access to an experimental therapy.
This trial tests a new drug, elranatamab, for people with multiple myeloma who recently received a CAR-T cell therapy (cilta-cel) but still have high-risk features. The goal is to see if elranatamab can help keep the cancer from coming back.
This trial tests a new medicine called elranatamab in people whose multiple myeloma has come back after they tried other treatments, including a specific type of immunotherapy (anti-CD38) and the drug lenalidomide. The goal is to see if this medicine can help control the cancer.
This trial tests a new drug called teclistamab for people with plasmablastic lymphoma that has come back or not responded to standard treatments. The goal is to see if teclistamab can shrink tumors and control the disease.
Hear when a new Plasmablastic Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.